Bioconjugate companies develop technologies that chemically link biological molecules to drugs, imaging agents, polymers or other functional components. These approaches are used to improve targeting, stability, delivery and detection across therapeutics, diagnostics and life science research.
This category includes companies working on:
Browse 50 UK bioconjugate companies below.
Sterile injectable drug product development and fill-finish manufacturing
Curia is a global contract development and manufacturing organisation operating from the West of Scotland Science Park in Glasgow. The facility specialises in sterile injectable drug product development and GMP manufacturing, including complex formulation, lyophilisation, and fill-finish for clinical and…
Global CDMO for biologics development and manufacture
Lonza is one of the world's largest contract development and manufacturing organisations, providing services across biologics, cell and gene therapy, and small molecules. Its primary UK site in Slough is a multi-product cGMP facility specialising in mammalian biopharmaceutical development and manufacture. The…
Shark-derived single-domain antibody biologics for cancer and inflammation
Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from the shark immune system. soloMERs offer advantages over conventional antibodies in size, stability, and tissue penetration. The pipeline…
Structural and physicochemical characterisation CRO for biopharmaceuticals
BioPharmaSpec is a contract research organisation specialising in the structural and physicochemical characterisation of biopharmaceuticals during discovery and preclinical development. Using mass spectrometry, chromatography and spectroscopy, it analyses monoclonal antibodies, biosimilars, antibody-drug conjugates,…
Novel ADC payloads targeting NMT enzymes in cancer
Myricx Bio is a clinical-stage biotechnology company developing a novel class of antibody-drug conjugate payloads based on inhibition of N-myristoyltransferase, an enzyme essential to cancer cell survival. Its NMTi payload chemistry platform addresses limitations of existing ADC payloads, including resistance and…
Fluorescent nanoparticle probes and antibody conjugation reagents
Stream Bio is a developer and manufacturer of fluorescent conjugated polymer nanoparticles for biological imaging and diagnostic research. Its visible and near-infrared probes support microscopy, flow cytometry, immunoassays and lateral-flow test development. The company supplies streptavidin-linked reagents and…
Sustainable conjugation technology for antibody-drug conjugate manufacturing
Vitamab is a Manchester-based biotechnology company developing conjugation technology to strengthen the antibody-drug conjugate manufacturing supply chain. Its proprietary system uses accessible, lower-toxicity materials in place of scarce or hazardous reagents, aiming to reduce production costs and environmental…
Protein superglue vaccine platform targeting infectious disease and cancer
SpyBiotech is a clinical-stage biotechnology company developing vaccines using its proprietary protein superglue technology, which enables efficient and stable attachment of antigens to virus-like particle and viral vector delivery platforms. The approach improves immunogenicity and reduces manufacturing complexity…
Contract development and manufacturing of complex small molecule APIs and ADCs
Sterling Pharma Solutions is a contract development and manufacturing organisation specialising in complex small molecule active pharmaceutical ingredient development and cGMP manufacturing for the pharmaceutical and biotech industries. Capabilities include hazardous and high-potency chemistry, flow chemistry,…
Next-generation ADC linker chemistry for precision cancer therapeutics
Siftr Bio is a biotechnology company developing novel linker chemistry for antibody-drug conjugates. Current ADC linkers have limited diversity and insufficient selectivity, contributing to off-target toxicity that restricts their therapeutic application. Siftr's platform screens enzyme-responsive linker candidates…